Cystic Fibrosis (CF) Market : Key Trends and Forecast Research Report 2017 to 2023
Study on Cystic Fibrosis (CF) Market by Infinium
Global research is comprehensive presentation of qualitative and quantitative
research to identify key trends, growth prospects, drivers, restraints and
opportunities in the Global market. The report also deep dives into the sub-segments
of Cystic Fibrosis Market by drug
class(CFTR modulators, mucolytics, pancreatic enzyme supplements and
bronchodilators), by route of administration(inhaled drugs and oral drugs)
through main geographies in the Global Market such as North America, Europe,
Asia-Pacific and RoW. Browse through over 100 tables and figures to get
complete view of the global and regional markets of Cystic Fibrosis over the period of 2017 to 2023.
Cystic fibrosis is
a genetic disease that causes continuous lung infections and breathing problem
over time. It is a progressive disease. The presence of imperfect gene causes a
thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and
other organs. The mucus in the lungs clogs airways and traps bacteria leading
to an infection that causes savior lung damage, and respiratory failure. The
mucus prevents in the pancreas discharge the digestive enzymes that allow the
body to break down food and absorb vital nutrients. This disease is caused by
mutation in gene, cystic fibrosis Trans membrane conductance regulator (CFTR)
is a membrane protein in vertebrates, a protein required for regulating sweat,
mucus and body secretions.
Get a Sample Report @ https://www.infiniumglobalresearch.com/Reports/MakeSampleRequest/35
Market Insights
The global Cystic
fibrosis market was sized over USD 2.15 billion in 2015. The global Cystic
fibrosis market is projected to reach USD 6.67 billion by 2023, growing with a
CAGR between 15% and 15.4% from 2017 to 2023. The global market for cystic
fibrosis is driven by continued growth of the number of CF patients worldwide.
Increasing awareness for cystic fibrosis therapy, technological developments in
the R&D and increase in the occurrence of cystic fibrosis are some of the
factors likely to drive the global Cystic fibrosis market over the forecast
period. However, high cost of treatment and R&D, complicated
pathophysiology, and increase in genetic mutation rate are the prime
restraining factors to the growth of global Cystic fibrosis market. Nevertheless,
rising number of initiatives taken by nonprofit organizations, and presence of
flexible policies are will bring more opportunities to the global Cystic
fibrosis market over the forecast period.
Segments Covered:
The report segments
the global Cystic fibrosis market by drug class, by route of administration and
by region. The global Cystic fibrosis market is segmented on the basis of drug
class as CFTR Modulators, Mucolytics, Pancreatic enzyme supplements and
Bronchodilators. The CFTR modulator drug class was estimated to account for
approximately 44%% of total CF drug revenue share in 2015. On the basis of
route of administration it is segmented by inhaled drugs and oral drugs. Oral
route accounted for the largest share of nearly 62.7% in 2015.
Company
Profiles
· Vertex
Pharmaceuticals Incorporated
· Gilead,
AbbVie Inc
· Novartis AG
· F.
Hoffmann-La Roche Ltd
· Alaxia
· Merck &
Co. Inc.
· AIT (Advanced
Inhalation Therapies)
· ALLERGAN.
· AstraZeneca
· Teva
Pharmaceutical Industries Ltd
· Alcresta.
Key topics covered:
1. Preface
2. Executive
Summary
3. Global Cystic
fibrosis Market Overview
4. Global Cystic
fibrosis Market: IGR Snapshots
5. Global Cystic
fibrosis market by Drug Class (USD Million) 2017 – 2023
6. Global Cystic
fibrosis market by Route of Administration (USD Million) 2017 – 2023
7. Global Cystic
fibrosis Market Analysis, by Region (USD Million) 2017 – 2023
8. Company Profiles
Click to View Complete
Report @ https://www.infiniumglobalresearch.com/healthcare_medical_devices/cystic_fibrosis_cf_market
Comments
Post a Comment